MMCM
CPRX

Murphy & Mullick Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Murphy & Mullick Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,150
Closed -$28.5K – 687
2026
Q1 		$28.5K Hold
1,150
– – 0.02% 359
2025
Q4 		$26.8K Hold
1,150
– – 0.02% 369
2025
Q3 		$24.1K Hold
1,150
– – 0.02% 368
2025
Q2 		$25K Hold
1,150
– – 0.02% 351
2025
Q1 		$27.9K Hold
1,150
– – 0.03% 327
2024
Q4 		$24K Buy
+1,150
New +$24.7K 0.02% 336

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Murphy & Mullick Capital Management's CPRX Position: Q2 2026 in Review

Murphy & Mullick Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 1,150 shares — an estimated $28.5K sold.

Murphy & Mullick Capital Management first reported a position in CPRX in Q4 2024 and held it in 6 quarters. The position peaked at $28.5K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Murphy & Mullick Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 1,150 Catalyst Pharmaceutical shares in Q2 2026, an estimated $28.5K.
  • Murphy & Mullick Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 6 quarters.
  • Murphy & Mullick Capital Management's Catalyst Pharmaceutical position peaked at $28.5K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.